MedTrace Logo

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

NCT07327411 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-08

No results posted yet for this study

Summary

This study is a single-arm, multi-center, prospective clinical study aimed at exploring the efficacy and safety of cetuximab β combined with PRaG regimen in rescuing patients with EGFR-positive advanced refractory solid tumors.

Conditions

  • Advanced Refractory Solid Tumors

Interventions

RADIATION

Hypofractionated radiotherapy

10-24Gy/5-8Gy/2-3f

DRUG

PD-L1 inhibitor

400mg，q3w, until PD

DRUG

GM-CSF

200μg, D1-D7, q3w，≥8 cycles

DRUG

anti-EGFR monoclonal antibody

500mg/m2 ，d1 ，q3w，≥8 cycles

Sponsors & Collaborators

  • Second Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • liyuan zhang, PhD · Second Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-27
Primary Completion
2027-02-10
Completion
2027-11-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07327411 on ClinicalTrials.gov